Celtrix Receives Additional Patent On SomatoKine, Its IGF-BP3 Complex.SANTA CLARA, Calif.--(BUSINESS WIRE)--June 24, 1996--Celtrix Pharmaceuticals, Inc. (Nasdaq: CTRX CTRX Contractions (labor & delivery) ) announced today that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has granted the company another use patent on its IGF-BP3 complex, SomatoKine(R). The company now has seven issued or allowed U.S. patents and thirteen families of patent applications related to the composition, production and methods of use for SomatoKine. The new U.S. patent No. 5,527,776 relates to methods for the treatment of hematologic disorders hematologic disorders, n.pl the diseases of the blood and blood-forming tissues. . This patent claims a method of treating hemoglobin-deficient anemia by administering a complex of insulin-like growth factor-I (IGF-I IGF-I see somatomedin C. IGF-I Insulin-like growth factor I, somatomedin-C A polypeptide hormone structurally similar to proinsulin, synthesized in the liver and fibroblasts, giving fibroblasts a paracrine function; serum levels correlate with ) and its major binding protein (BP3). Several indications of interest to the company are accompanied by varying degrees of anemia. SomatoKine is the recombinant equivalent of the natural complex formed by IGF-I and its binding protein, BP3. The active portion, IGF-I, is an anabolic anabolic pertaining to or arising from anabolism. anabolic steroid steroids with a tissue-building effect. Testosterone is an example of a natural anabolic steroid with the, sometimes undesirable, effect of causing masculinization. hormone that plays a key role in diverse biological processes, including tissue repair, organ function, and muscle and bone formation. Celtrix has recently shown in a Phase I human clinical study that SomatoKine allows for the safe administration of IGF-I at doses many times higher than have ever been possible before. As demonstrated in preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. , this may significantly increase the efficacy of therapy. The company's goal is to replenish or enhance the natural reservoir of IGF-I, which can become seriously depleted de·plete tr.v. de·plet·ed, de·plet·ing, de·pletes To decrease the fullness of; use up or empty out. [Latin d by severe trauma, chronic disease or aging. Celtrix is a biopharmaceutical company developing novel therapeutics for seriously debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction , degenerative conditions primarily associated with severe trauma, chronic diseases or aging. Company programs are focused on the use of SomatoKine, a novel IGF-BP3 complex, to treat destructive metabolic processes (catabolism catabolism (kətăb`əlĭz'əm), subdivision of metabolism involving all degradative chemical reactions in the living cell. ) in acute indications such as major surgery, organ damage/failure and traumatic injury. Potential chronic indications could include osteoporosis, chronic renal (kidney) failure, and wasting conditions associated with cancer and AIDS. Through strategic alliances with Celtrix, The Green Cross Corporation is developing SomatoKine for the treatment of osteoporosis in Japan, and Genzyme Corporation is developing TGF- beta-2 as part of a comprehensive approach to tissue repair and the treatment of systemic disease. This press release contains certain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Actual results may differ materially from the statements made, as a result of various factors, including risks associated with future company research, clinical results, the regulatory approval process, competitive products and other factors which are listed from time to time in Celtrix's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent Celtrix's judgment as of the date of this release. CONTACT Celtrix Pharmaceuticals, Inc. David M. Rosen Ph.D., (V.P., R&D) 408/988-2500 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion